Medical Risk-Aversion Can Kill, Too
Yet in medicine, especially when it comes to pharmaceuticals and cutting-edge therapies, we seem to forget this logic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Craig-Hallum Reiterates a Buy Rating on Clover Health Investments (CLOV), Sets a $6 PT
Clover Health Investments, Corp. (NASDAQ:CLOV) is one of the 13 Stocks Under $5 With High Upside Potential. In a report released on May 7, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Clover Health Investments, Corp. (NASDAQ:CLOV) with a price target of $6.00. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company reported notable fiscal Q1 2025 results that support this optimistic outlook, with Medicare Advantage membership for the quarter reaching 103,418, representing a 30% year-over-year increase. Total revenue for fiscal Q1 2025 rose 33% year-over-year to $462 million, while adjusted EBITDA reached $26 million, reflecting a significant 279% year-over-year rise. Adjusted net income also grew 322% year-over-year to $25 million. In addition, Clover Health Investments, Corp. (NASDAQ:CLOV) reported a GAAP net loss of $1 million, compared to $19 million a year ago, suggesting a considerable improvement in its operations. Clover Health Investments, Corp. (NASDAQ:CLOV) is a physician enablement technology company that offers Medicare Advantage plans in the United States. It offers PPO and HMO Medicare Advantage plans in several US states. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3
Opko Health Inc. (NASDAQ:OPK) is one of the 13 Stocks Under $5 With High Upside Potential. On May 1, analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK), retaining the price target of $3.00. Despite mixed fiscal Q1 2025 results, the rating was supported by future prospects and strategic developments undertaken by the company. A doctor in scrubs discussing a patient's test results with a small group of concerned family members. Although Opko Health Inc. (NASDAQ:OPK) reported a decline in consolidated total revenue to $149.9 million in fiscal Q1 2025, the analyst sees potential in its future guidance. Management expects total revenue for full year 2025 to be in the $675-685 million range. In addition, Chen expects the pending transaction with Labcorp to close in the third quarter of 2025, thereby increasing profitability and streamlining BioReference's operations. He further stated that a significant factor lending Opko Health Inc. (NASDAQ:OPK) a prominent position in the obesity and metabolic disorders treatment space is the advancement of an innovative oral dual agonist GLP-1/glucagon peptide. The company has plans to file an IND application later in the year. Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Morgan Stanley Maintains a Buy Rating on LifeStance Health (LFST), Keeps the PT at $10
LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the 13 Stocks Under $5 With High Upside Potential. On May 27, Morgan Stanley analyst Craig Hettenbach maintained a Buy rating on LifeStance Health Group, Inc. (NASDAQ:LFST), keeping the associated price target the same at $10. The analyst based the rating on the company's growth potential and strategic positioning, stating that LifeStance Health Group, Inc. (NASDAQ:LFST) is well-positioned to capitalize on the rising demand for outpatient mental health services. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. This trend is driven by reduced social stigma regarding seeking behavioral health care, along with a shift to in-network insurance coverage. According to the analyst, LifeStance Health Group, Inc. (NASDAQ:LFST) has a hybrid care model that mixes in-person and virtual visits, supporting this demand through increasing flexibility for both clinicians and patients. The analyst further reasoned that LifeStance Health Group, Inc. (NASDAQ:LFST) is focusing on long-term EBITDA margin expansion, and management is confident about its potential to attain 15%-20% margins, up from the current guidance of around 10% by 2025. Hettenbach expects various factors to drive this margin expansion, including center margins improvements, slower growth in general and administrative expenses relative to revenue, and the introduction of higher-margin services. LifeStance Health Group, Inc. (NASDAQ:LFST) provides outpatient mental health services, including psychological and neuropsychological testing, psychiatric evaluations and treatment, and individual, family, and group therapy. The company operates through a mental health platform and also offers virtual care via its online delivery platform, as well as in-person care at centers located in 32 US states. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
